Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study
Authors:
- 4 August 2018
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (6) , 844-848
Abstract
Background/aim: We previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis)AndPhotodynamicTherapyOnPolypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV).Methods: We reviewed medical records of patientsrandomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the investigator’s discretion after release from the 2-year LAPTOP study up to 5years. We evaluated visual acuity (VA), continuity of initial treatment, percentage of dry macula achievement and macular atrophy at 5 years.Results: The logarithm of minimal angle of resolution VA was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline (p=0.101) and was 0.55 and 0.28 at 5years, respectively (p2, respectively (p=0.155).Conclusions: The better VA in the initial ranibizumab group compared with the PDT group at 2 years was retained at the 5-year follow-up.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyJAMA Ophthalmology, 2017
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2014
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZONOphthalmology, 2013
- Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study ResultsAmerican Journal of Ophthalmology, 2013
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- The Significance of External Limiting Membrane Status for Visual Acuity in Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2010
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Indocyanine Green Angiography: Guided Photodynamic Therapy for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2007
- Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfinGraefe's Archive for Clinical and Experimental Ophthalmology, 2005